Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from GREES

Éric Abadie(Ifremer), Jean‐Yves Reginster(University of Liège), Y Tsouderos(Servier (France)), Roy D. Altman, G Bouvenot, Jean-Pierre Devogealer, B. Mitlak(Eli Lilly (United States)), Jaime Branco(Hospital de Egas Moniz), Andrea Laslop, J.-D. Ringe, L. Vanhaelst, W. Dere, John J. Orloff, D Ethgen, Philippe M. Vanderauwera, C J Menkès, Bernard Avouac, Pierre Delmas(Université Claude Bernard Lyon 1), Gottfried Kreutz

ORBi (University of Liège)

March 1, 2005

Cited by 0

Related Papers

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

|New England Journal of Medicine|2009|3.4k

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

|Osteoporosis International|2012|2.9k

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

|Osteoporosis International|2018|1.8k

EULAR evidence-based recommendations for the management of fibromyalgia syndrome

|Annals of the Rheumatic Diseases|2007|751

Incorporation and distribution of strontium in bone

|Bone|2001|582